Northern Trust Corp Pep Gen Inc. Transaction History

Northern Trust Corp

$690 Billion
Q4 2024

A detailed history of Northern Trust Corp transactions in Pep Gen Inc. stock. As of the latest transaction made, Northern Trust Corp holds 157,038 shares of PEPG stock, worth $226,134. This represents 0.0% of its overall portfolio holdings.

Number of Shares

157,038

Previous 149,054 5.36%

Holding current value

$226,134

Previous $1.27 Million 53.22%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$3.63 - $9.93 $28,981 - $79,281	7,984 Added 5.36%	157,038 $596,000
Q3 2024 Nov 13, 2024	BUY	$7.75 - $18.55 $399,675 - $956,642	51,571 Added 52.9%	149,054 $1.27 Million
Q2 2024 Aug 14, 2024	BUY	$10.54 - $18.14 $55,735 - $95,924	5,288 Added 5.74%	97,483 $1.56 Million
Q1 2024 May 14, 2024	BUY	$6.63 - $17.3 $115,163 - $300,501	17,370 Added 23.21%	92,195 $1.36 Million
Q4 2023 Feb 13, 2024	BUY	$3.86 - $7.96 $347 - $716	90 Added 0.12%	74,825 $508,000
Q3 2023 Nov 13, 2023	SELL	$5.0 - $9.09 $111,300 - $202,343	-22,260 Reduced 22.95%	74,735 $379,000
Q2 2023 Aug 11, 2023	SELL	$8.94 - $16.39 $138,283 - $253,520	-15,468 Reduced 13.75%	96,995 $867,000
Q1 2023 May 15, 2023	SELL	$11.44 - $17.7 $14,688 - $22,726	-1,284 Reduced 1.13%	112,463 $1.38 Million
Q4 2022 Feb 13, 2023	BUY	$9.31 - $16.57 $384,614 - $684,539	41,312 Added 57.03%	113,747 $1.52 Million
Q3 2022 Nov 14, 2022	BUY	$4.86 - $12.75 $12,111 - $31,773	2,492 Added 3.56%	72,435 $658,000
Q2 2022 Aug 12, 2022	BUY	$9.0 - $12.89 $629,487 - $901,565	69,943 New	69,943 $694,000

Others Institutions Holding PEPG

# of Institutions

Shares Held

24.7M

Call Options Held

Put Options Held

15K

View Full List

About PepGen Inc.

Ticker PEPG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,631,900
Market Cap $34M
Description
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is a...

More about PEPG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Pep Gen Inc. Transaction History